European Union
-
Amgen’s Repatha receives positive EU opinion for expanded cardiovascular use
Repatha lowers low-density lipoprotein cholesterol (LDL-C), a key risk factor for cardiovascular disease, alongside other measures to manage cardiovascular risk.
-
Kyowa Kirin extends Crysvita EU orphan market exclusivity to February 2030
The approval follows a positive recommendation issued in April 2026 by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
-
BrightHeart secures EU regulatory clearance for prenatal screening AI
BrightHeart will officially introduce the platform to European clinicians during the Fetal Medicine Foundation (FMF) World Congress in Vienna, taking place from June 28 to July 2, 2026.
-
AbbVie seeks EU approval to expand MAVIRET use for acute Hepatitis C treatment
If approved, MAVIRET would become one of the few therapies in the European Union indicated for both acute and chronic HCV infection.
-
Africa CDC backs US$180M Biovac deal to end vaccine import dependence
The financing consortium includes Proparco, the European Investment Bank through the Human Development Accelerator initiative, and the International Finance Corporation.
-
Africa CDC, European Union launch USD108M Global Gateway health initiatives
The partnership aligns with Africa CDC’s Health Security and Sovereignty Agenda, which seeks to help African countries build stronger systems that can prevent, detect, and respond to disease threats while reducing reliance on external support.
-
